Treatment of nonoccupational limb and trunk dystonia with botulinum toxin
Identifieur interne : 005565 ( Main/Exploration ); précédent : 005564; suivant : 005566Treatment of nonoccupational limb and trunk dystonia with botulinum toxin
Auteurs : Quirk [Royaume-Uni] ; G. L. Sheean [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1996-07.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Botulinum Toxins, Type A (administration & dosage), Botulinum toxin, Disability Evaluation, Dose-Response Relationship, Drug, Dystonia (drug therapy), Dystonia (etiology), Electromyography (drug effects), Female, Humans, Injections, Intramuscular, Limb dystonia, Male, Middle Aged, Neurologic Examination (drug effects), Pain Measurement, Treatment, Treatment Outcome, Trunk dystonia.
- MESH :
- chemical , administration & dosage : Botulinum Toxins, Type A.
- drug effects : Electromyography, Neurologic Examination.
- drug therapy : Dystonia.
- etiology : Dystonia.
- Adolescent, Adult, Aged, Aged, 80 and over, Disability Evaluation, Dose-Response Relationship, Drug, Female, Humans, Injections, Intramuscular, Male, Middle Aged, Pain Measurement, Treatment Outcome.
Abstract
We report the results of treatment of 16 patients (14 women, two men; 18–81 years old) with nonoccupational limb and trunk dystonia with botulinum toxin A (BTX; Dysport). A total of 18 clinical problems were identified. Outcomes were assessed in terms of pain relief and improvement in posture and function by the combined observations of the patient and physician. Patients' satisfaction with treatment was high–the benefit in 15 of 18 problems was rated as good to excellent. Reduction in pain was achieved in nine of 10 painful problems, with total relief in four cases. Some normalisation of posture was obtained in 17 of 18; it was complete in three cases. Functional improvement was less common (10 of 18). Excessive weakness was the most common side effect, affecting five patients, but it was disabling in only two. We conclude that BTX can provide substantial benefit with minimal side effects in the majority of patients with these conditions, particularly with pain relief and postural improvements.
Url:
DOI: 10.1002/mds.870110405
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001E62
- to stream Istex, to step Curation: 001E62
- to stream Istex, to step Checkpoint: 003A66
- to stream PubMed, to step Corpus: 004815
- to stream PubMed, to step Curation: 004815
- to stream PubMed, to step Checkpoint: 004749
- to stream Ncbi, to step Merge: 004B67
- to stream Ncbi, to step Curation: 004B67
- to stream Ncbi, to step Checkpoint: 004B67
- to stream Main, to step Merge: 008670
- to stream Main, to step Curation: 005565
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of nonoccupational limb and trunk dystonia with botulinum toxin</title><author><name sortKey="Quirk" sort="Quirk" uniqKey="Quirk" last="Quirk">Quirk</name></author><author><name sortKey="Sheean, G L" sort="Sheean, G L" uniqKey="Sheean G" first="G. L." last="Sheean">G. L. Sheean</name></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name></author><author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">Andrew Lees (neurologue)</name><affiliation><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8F3F4E84E8D221FEA1E74706D369CB135631A767</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1002/mds.870110405</idno><idno type="url">https://api.istex.fr/document/8F3F4E84E8D221FEA1E74706D369CB135631A767/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001E62</idno><idno type="wicri:Area/Istex/Curation">001E62</idno><idno type="wicri:Area/Istex/Checkpoint">003A66</idno><idno type="wicri:doubleKey">0885-3185:1996:Quirk:treatment:of:nonoccupational</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8813216</idno><idno type="wicri:Area/PubMed/Corpus">004815</idno><idno type="wicri:Area/PubMed/Curation">004815</idno><idno type="wicri:Area/PubMed/Checkpoint">004749</idno><idno type="wicri:Area/Ncbi/Merge">004B67</idno><idno type="wicri:Area/Ncbi/Curation">004B67</idno><idno type="wicri:Area/Ncbi/Checkpoint">004B67</idno><idno type="wicri:doubleKey">0885-3185:1996:Quirk J:treatment:of:nonoccupational</idno><idno type="wicri:Area/Main/Merge">008670</idno><idno type="wicri:Area/Main/Curation">005565</idno><idno type="wicri:Area/Main/Exploration">005565</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of nonoccupational limb and trunk dystonia with botulinum toxin</title><author><name sortKey="Quirk" sort="Quirk" uniqKey="Quirk" last="Quirk">Quirk</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>National Hospital for Neurology and Neurosurgery, London</wicri:cityArea></affiliation></author><author><name sortKey="Sheean, G L" sort="Sheean, G L" uniqKey="Sheean G" first="G. L." last="Sheean">G. L. Sheean</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>National Hospital for Neurology and Neurosurgery, London</wicri:cityArea></affiliation></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>National Hospital for Neurology and Neurosurgery, London</wicri:cityArea></affiliation><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>Institute of Neurology, London</wicri:cityArea></affiliation></author><author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">Andrew Lees (neurologue)</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>National Hospital for Neurology and Neurosurgery, London</wicri:cityArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1996-07">1996-07</date><biblScope unit="vol">11</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="377">377</biblScope><biblScope unit="page" to="383">383</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8F3F4E84E8D221FEA1E74706D369CB135631A767</idno><idno type="DOI">10.1002/mds.870110405</idno><idno type="ArticleID">MDS870110405</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Botulinum Toxins, Type A (administration & dosage)</term><term>Botulinum toxin</term><term>Disability Evaluation</term><term>Dose-Response Relationship, Drug</term><term>Dystonia (drug therapy)</term><term>Dystonia (etiology)</term><term>Electromyography (drug effects)</term><term>Female</term><term>Humans</term><term>Injections, Intramuscular</term><term>Limb dystonia</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Pain Measurement</term><term>Treatment</term><term>Treatment Outcome</term><term>Trunk dystonia</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins, Type A</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Electromyography</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dystonia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disability Evaluation</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Injections, Intramuscular</term><term>Male</term><term>Middle Aged</term><term>Pain Measurement</term><term>Treatment Outcome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We report the results of treatment of 16 patients (14 women, two men; 18–81 years old) with nonoccupational limb and trunk dystonia with botulinum toxin A (BTX; Dysport). A total of 18 clinical problems were identified. Outcomes were assessed in terms of pain relief and improvement in posture and function by the combined observations of the patient and physician. Patients' satisfaction with treatment was high–the benefit in 15 of 18 problems was rated as good to excellent. Reduction in pain was achieved in nine of 10 painful problems, with total relief in four cases. Some normalisation of posture was obtained in 17 of 18; it was complete in three cases. Functional improvement was less common (10 of 18). Excessive weakness was the most common side effect, affecting five patients, but it was disabling in only two. We conclude that BTX can provide substantial benefit with minimal side effects in the majority of patients with these conditions, particularly with pain relief and postural improvements.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement><orgName><li>National Hospital for Neurology and Neurosurgery</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Quirk" sort="Quirk" uniqKey="Quirk" last="Quirk">Quirk</name></region><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">Andrew Lees (neurologue)</name><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><name sortKey="Sheean, G L" sort="Sheean, G L" uniqKey="Sheean G" first="G. L." last="Sheean">G. L. Sheean</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005565 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005565 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8F3F4E84E8D221FEA1E74706D369CB135631A767
|texte= Treatment of nonoccupational limb and trunk dystonia with botulinum toxin
}}
| This area was generated with Dilib version V0.6.23. |  |